Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Nestle, Coke, Danone take cautious approach to catering to Ozempic users

<html xmlns="http://www.w3.org/1999/xhtml"><head><title>FOCUS-Nestle, Coke, Danone take cautious approach to catering to Ozempic users</title></head><body>

Updates headline, no changes to text

By Jessica DiNapoli

NEW YORK, June 20 (Reuters) -Nestle's NESN.S new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters.

The world's largest food maker is keeping the names of the drugs off the packaging due to regulatory concerns, Tom Moe, Nestle USA's president of meals, said in a recent interview. Nestle will instead market its Vital Pursuit line of $5-and-under frozen meals on social media, he said.

"We won’t directly make the connection (to the drugs) on the food package," Moe said.

Nestle's hesitancy to name drugs like Novo Nordisk's NOVOb.CO Wegovy and Ozempic on its packaging shows the uncertainty facing global food companies as they place big bets on selling products specifically geared toward millions of people taking the appetite-suppressing medicines.

The medications, from a class of drugs known as GLP-1 agonists, threaten to dent profits of snack-makers and fast food chains as people taking them cut way back on the amount of food they consume.

When its fajita melts and pizzas hit store freezers this autumn, Nestle will face a sea of competitors making specific claims about their products targeting people on the medications.

The maker of Biocare, a drink that sells for $4.50 per serving, touts on the packaging that it can "alleviate side effects" such as nausea, for people taking semaglutides, a reference to the active ingredient in Wegovy and Ozempic.

The medications can cause gastrointestinal side effects, but doctors recommend people using them keep eating, especially protein-rich foods, to maintain energy and avoid losing muscle.

Herbalife HLF.N pitches shakes sold in a bundle for $185.10 that it claims can help people achieve their nutritional needs while on "the shot," as the injectable drugs are sometimes colloquially called.

Retailers like supplement-seller GNC are also looking to capitalize on the trend by introducing a section in stores dedicated to GLP-1 users, selling protein powder and fiber.

Referencing the weight-loss drugs on packaging for Vital Pursuit products could expose Nestle to regulatory scrutiny.

"We're not a medication, we're a food product," Moe said.

Referring to the medications could suggest that the food somehow treats or prevents disease, claims only drugs approved by the U.S. Food and Drug Administration can make, said Lauren Handel, an attorney specializing in food.

"It's a tricky area where you'd want to be careful about what you say," Handel said. "The safest course of action is not to mention any drugs."

The same rules apply to advertising, she said. Labeling items as "suitable for people on a diet" or as "companions" to the medications may comply with FDA regulations. "Some companies will take more risk," she said.

Nestle declined to say whether it will refer to the drugs in advertisements.


Herbalife is taking a more direct approach, saying on Facebook: "Using a GLP-1 weight-loss drug? Support your nutritional needs by using Herbalife's GLP-1 Companion Pack."

Robard Corp, which makes Biocare, said it is marketing the drink through a "strong influencer community who are all taking GLP-1s." Other drugs in the class include Eli Lilly's LLY.N Mounjaro and Zepbound.

Biocare influencer Ashley Dunham of Jacksonville, Florida, said in a TikTok video the product has been an "absolute game changer" when it comes to maintaining her weight after losing 100 pounds (45.4 kilograms).

Coca-Cola KO.N and yogurt-maker Danone DANO.PA say many of their products are perfect for people taking the medications because they are either low in sugar or high in protein.

Coke's Fairlife shakes, with up to 42 grams of protein, are frequently touted by social media influencers using the medications.

Fairlife does not have any paid partners or influencers who link the shakes with GLP-1s or weight loss, and does not target them with free products or other incentives, a spokesperson said.

Healthy Choice meal maker Conagra Brands CAG.N also will keep drug names off packaging for food marketed to people using the medications, executives told Reuters this month.

Using the names could turn off those who aren't taking the drugs but would still consider buying the food, said Megan Bullock, a director of strategic insights at Conagra.

Conagra will focus on attributes of its existing products such as protein or fiber content to help consumers using GLP-1s make the connection that the food is suitable for them, said Bob Nolan, the company's vice president of demand science.

Conagra is not currently developing new brands for people using the medications but executives have said it sees opportunity to sell more frozen meals to them.

Kelli Frias, a marketing professor at American University, said consumers do not yet have clear ideas of what to eat while on the medications.

Food companies are “trying to create new associations,” she said. "We don't have those associations in our mind until we're taught them."

Reporting by Jessica DiNapoli in New York
Editing by Bill Berkrot


Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.